Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amgen to pay hefty...

    Amgen to pay hefty $13.4 billion for buying Celgene psoriasis drug Otezla

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-27T09:15:27+05:30  |  Updated On 27 Aug 2019 9:15 AM IST
    Amgen to pay hefty $13.4 billion for buying Celgene psoriasis drug Otezla

    Amgen, which announced the deal on Monday, is paying a hefty price for the drug, analysts and investors said. Still, Otezla will deliver growth for the company right away and its shares rose around 2 per cent in early trading.


    U.S: Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.


    Amgen, which announced the deal on Monday, is paying a hefty price for the drug, analysts and investors said. Still, Otezla will deliver growth for the company right away and its shares rose around 2 per cent in early trading.


    Bristol-Myers and Celgene's shares were both up around 3 per cent.


    Bristol-Myers said in June that it would sell Otezla to allay concerns raised by the Federal Trade Commission because of a competing treatment that it is developing. Analysts said at the time that they were expecting Otezla to sell for around $8 billion to $10 billion.


    Bristol-Myers said in a statement that there was significant interest from multiple potential buyers from early on in the process.


    Otezla brought in sales of $1.61 billion last year. Amgen said it expected the drug's sales to grow at least in the low-double digits over the next five years.


    Jeff Jonas, healthcare portfolio manager at Gabelli funds, said that a number of Amgen's current drugs face a loss of patent protection and competition from biosimilar drugs, so the growth from Otezla would be welcome.


    "This is an attractive product for them that fits more or less with their current portfolio," he said. "It's an approved product with a good safety profile, so there's not a lot of risks."


    Still, he expressed some skepticism about Amgen's growth forecast for the drug, noting that new competitors, including Bristol-Myers' drug in development, are likely to eat into its market share.


    Amgen said it expects the deal to produce tax benefits with a present cash value of $2.2 billion, reducing the actual deal total to $11.2 billion.


    Bristol-Myers said most of the proceeds from the sale will go to pay down debt from the Celgene deal. It also increased a previously planned $5 billion accelerated share buyback to $7 billion.


    By Michael Erman and Manas Mishra


    Read Also: Amgen wins a patent battle against Novartis for blockbuster arthritis drug Enbrel

    Amgenbiosimilar drugsBristol-MyersCelgeneCelgene psoriasis drugFederal Trade CommissionHealthcareJeff JonasOtezlapharmapharma companypharma news
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok